As of December 31, 2024, Neovacs SA has 269,590.00 shares outstanding.
| Shares Outstanding | 269,590.00 |
As of December 31, 2024, Neovacs SA maintains a current ratio of 0.63, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.63 |
| Quick Ratio | 0.11 |
| Debt / Equity | 1.28 |
These figures cover the twelve months ended December 31, 2024.
| Employee Count | 19.00 |
These figures are as of the close on October 22, 2026.
| 50-Day Moving Average | 0.28 |
As of December 31, 2024, Neovacs SA holds 435,449.00 in cash and equivalents against 230,367.00 in total debt, resulting in a net debt position of -205,074.00. Total book value stands at 18.06M, with working capital of -1.50M providing operational flexibility.
| Cash & Cash Equivalents | 435,449.00 |
| Total Debt | 230,367.00 |
| Net Debt | -205,074.00 |
| Equity (Book Value) | 18.06M |
| Book Value Per Share | 67.00 |
| Working Capital | -1.50M |
Neovacs SA's most recent stock split took place on June 23, 2026.
| Last Split Date | 6/23/2026 |
Already premium?